Maxion Therapeutics, a British biotech company, has closed an oversubscribed Series A funding round, raising $72 million. Led by General Catalyst with participation from new investors, the round will support Maxion’s proprietary KnotBody technology and its potential to address global markets through antibody-based therapies.

The company’s KnotBody platform targets ion channel- and GPCR-driven diseases. Its lead candidate, MAX001, is in preclinical development and aims to treat inflammatory conditions such as atopic dermatitis and inflammatory bowel disease. Additional early-stage programmes focus on pain management and cardiovascular disease, further expanding Maxion’s therapeutic pipeline.